Alzheimer's Drug Aduhelm Faces Crucial Medicare Decision
Medicare officials are trying to determine whether to cover Aduhelm, which the F.D.A. approved despite unclear evidence that it helps patients.
Source: nytimes.com
Page 31 - Aduhelm News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Aduhelm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Aduhelm Today - Breaking & Trending Today
How to Cope With Medicare's Rising Costs - The New York Times
A higher Medicare premium in 2022 is just part of the puzzle of health care costs for older Americans. But there are ways to plan.
Source: nytimes.com
Japan health ministry refuses to approve new Alzheimer's drug
A panel at Japan's health ministry refused to approve on Dec. 22 a new Alzheimer's disease drug jointly developed by Japan's Eisai Co. and U.S. firm Biogen Inc., saying more data are needed to judge its effectiveness.
Source: kyodonews.net
Biogen Announces Reduced Price for Aduhelm to Improve Access For Patients With Early Alzheimer's Disease In The United States
TOKYO, Dec 21, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that, effective January 1, 2022, Biogen will reduce the wholesale acquisition cost (WAC) of ADUHELM (aducanumab-avwa) 100 mg/mL injection
Source: finanznachrichten.de
Maker Cuts Price of Controversial New Alzheimer's Drug in Half
MONDAY, Dec. 20, 2021 (HealthDay News) -- The maker of the pricey new Alzheimer's drug Aduhelm (aducanumab) said Monday it will slash the cost of its medication in half, effective
Source: kulr8.com